Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.

Vaccine
Ravinder KaurMichael E Pichichero

Abstract

Serotypes 22F and 33F have been added to a new pneumococcal-conjugate vaccine (PCV-15) because of their prevalence in causing invasive pneumococcal diseases (IPD). We measured anti-polysaccharide 22F, 33F, 19A and 6A antibodies in children before and after pneumococcal colonization and acute otitis media (AOM) episodes caused by these specific-serotypes. A two-step method for construction of correlate of protection (COP) models included using a generalized estimating equation for the relationship between antibody level, age and colonization history followed by logistic-regression modelling that included colonization or AOM episodes as independent variables, and age adjusted antibody level as the predictor. A vaccine-induced serum antibody level of 0.45 μg/ml for 22F, 0.51 μg/ml for 6A and 4.1 μg/ml for 19A correlated with prevention of pneumococcal colonization by respective serotypes (insufficient number of cases for 33F to find COP against colonization). Antibody levels of 0.25 μg/ml for 22F, 33F and 6A and 2 μg/ml for 19A correlated with prevention of AOM by the respective serotypes. A COP threshold of anti-22F, 33F, 19A and 6A serum antibodies for NP colonization and AOM in young children can be derived using GEE and logist...Continue Reading

References

Sep 9, 1999·The Journal of Infectious Diseases·N MbelleK P Klugman
Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Faryal GhaffarGeorge H McCracken
Sep 5, 2006·Journal of Clinical Pathology·Paul BalmerRay Borrow
Feb 6, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A M Mitchell, T J Mitchell
May 14, 2010·Clinical and Vaccine Immunology : CVI·Stanley A Plotkin
Feb 15, 2012·The Pediatric Infectious Disease Journal·Robert CohenEmmanuelle Varon
Mar 24, 2012·Future Microbiology·Nicola PrincipiSusanna Esposito
Jan 1, 2013·Trends in Microbiology·Joshua R ShakKeith P Klugman
Jul 19, 2013·The Pediatric Infectious Disease Journal·Janet R CaseyMichael E Pichichero
Sep 11, 2013·Vaccine·Kari AuranenUNKNOWN Pneumococcal Carriage Group (PneumoCarr)
Dec 18, 2013·The Pediatric Infectious Disease Journal·Katherine E Fleming-DutraKatherine L O'Brien
Mar 29, 2014·The Pediatric Infectious Disease Journal·Anita M LoughlinStephen I Pelton
May 15, 2015·Human Vaccines & Immunotherapeutics·Nicola Principi, Susanna Esposito
Jun 19, 2015·Clinical Microbiology Reviews·K Aaron GenoMoon H Nahm
Jan 25, 2016·Folia Microbiologica·Muneki HotomiNoboru Yamanaka
Jul 27, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E UsufA Roca
Aug 9, 2017·Pediatrics·Ravinder KaurMichael E Pichichero
Oct 27, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Merryn VoyseyAndrew J Pollard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.